semaglutide for autoimmune disease as a potential therapeutic adjunct reducing flare-ups in Sjögren's syndrome: A case report GLP-1 Side Effects and Semaglutide:

The STEP-1 trial investigators noted that the majority of GI adverse events occurred during dose escalation and "typically resolved within a few days to weeks" [3]

Spanish law regarding the use of human subjects in clinical trials will be adhered to

Research protocols typically include: storage at low temperatures protection from excessive light controlled reconstitution methods sterile laboratory procedures Maintaining compound stability ensures reliable results during experimental studies

Within 5-10 years, the GLP-1 therapy landscape will likely include multiple oral options at various price points, fundamentally changing how metabolic disease is managed in primary care